Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or New Jersey for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to New Jersey only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. New Jersey (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Howard Fine (NPI 1295810059)

Field	Value
Entity Type	Individual
Organization	Howard Fine
Address	10 Plum St
City	New Brunswick
State	NJ
ZIP	08901
Taxonomy	Retina Specialist (Ophthalmology) Physician
NPI Enumerated	October 27, 2006

Payer Source	Total Paid
Medicare	$3.6M
Medicaid	$0

Key Findings

This provider has $3.6M in total Medicare revenue and no Medicaid billing on file, so the practice is effectively single‑payer with Medicare as the dominant revenue source; Medicaid does not appear in the billing record. That concentration means Medicare reimbursement policy and Part B drug payment rules will be the primary determinants of near‑term revenue performance.

Revenue is highly concentrated in intravitreal biologic administrations: the precomputed top three Medicare codes by revenue account for 59.0% of this provider's total Medicare revenue, with J0178 contributing $1.2M (34.0%), J2778 $574.2K (15.9%), and J2777 $328.9K (9.1%). This concentration indicates the practice’s economics are driven principally by anti‑VEGF and related retinal biologic treatments.

The clinical/service mix supports a retina specialty operation: high volumes for drug administration codes (J0178, J2778, J2777) are paired with the intravitreal injection procedure 67028 ($216.3K, 6.0%) and advanced retinal imaging 92134 ($114.5K, 3.2%). Together these codes describe a workflow centered on frequent office‑based injections supported by diagnostic OCT imaging and routine comprehensive ophthalmologic visits.

Competitive standing varies by product: J0178 ranks #641 of 3204 nationally (80th percentile; typical, unremarkable volume) while J2778 ranks #113 of 1208 (91th percentile; typical, unremarkable volume), and J2777 ranks #916 of 2039 (55th percentile; typical, unremarkable volume). In plain terms, the provider is an above‑median national participant for aflibercept and especially ranibizumab billing, while faricimab volume is closer to the national median.

There are striking high‑volume E/M and imaging outliers: 92014 generated 2.8K claims and $296.2K (8.2% of Medicare revenue) and ranks #79 of 35415 (100th percentile; extreme outlier), and 92134 produced 3.3K claims and $114.5K (3.2%) and ranks #298 of 26868 (99th percentile; extreme outlier). These placements signal exceptional throughput of comprehensive visits and retinal imaging relative to national peers, consistent with a high‑volume clinic model.

The provider also bills non‑specific biologic and unclassified drug codes at meaningful levels: J3590 accounts for $324.3K (9.0%) and ranks #225 of 631 (64th percentile; typical, unremarkable volume), and J3490 accounts for $130.1K (3.6%) and ranks #1302 of 2838 (53th percentile; typical, unremarkable volume). This pattern suggests additional billed biologics or office‑administered products beyond the main anti‑VEGF agents and some use of compounded agents (J7999 $6.8K).

Procedural and surgical activity is concentrated in in‑office injections rather than vitrectomy surgery: 67028 (intravitreal injection) is 2.2K claims and $216.3K (6.0%) and ranks #289 of 4255 (93th percentile; notably above typical national volume), while 67036 (vitrectomy access) is minimal at 14 claims and $9.2K (0.3%) and ranks #599 of 832 (22th percentile; typical, unremarkable volume). This split reinforces a practice model focused on frequent, office‑based therapeutic injections with limited surgical throughput.

The provider’s NPI was enumerated on 2006-10-27 (~20 years ago), indicating long tenure in the Medicare program; that longevity aligns with the established, high‑throughput injection and imaging volumes reported and supports interpretation of the provider as an experienced retina specialist with sustained Medicare activity.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

21 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0178	Injection, aflibercept, 1 mg	1,790	$690	$1.2M
J2778	Injection, ranibizumab, 0.1 mg	3,040	$190	$574.2K
J2777	Injection, faricimab‑svoa, 0.1 mg	11,340	$30	$328.9K
J3590	Unclassified biologics	150	$2,210	$324.3K
92014	An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group…	2,790	$110	$296.2K
Q5128	Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg	1,360	$220	$292.7K
67028	The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye.	2,210	$100	$216.3K
J3490	Unclassified drugs	60	$2,030	$130.1K
92134	The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes.	3,270	$40	$114.5K
99204	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider…	170	$130	$22.1K

Showing 1–10 of 21

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 21 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. New Jersey Distribution

Howard Fine — 5 of 21 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — New Jersey

Full comparison — all codes billed, vs. state median

21 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0178	12	90	880	$690	$693.6K
J2777	19	60	8,820	$30	$319K
J2778	2	40	1,140	$180	$240.8K
J3590	3	20	50	$2,180	$156.6K
Q5128	1	20	650	$210	$139K
67028	8	100	810	$100	$91.1K
92014	6	1,130	160	$100	$34.9K
J3490	61	120	70	$230	$30.2K
99214	11,078	13,640	130	$90	$23.6K
67036	15	20	20	$950	$19.9K

Showing 1–10 of 21

Related Providers

Other providers that share a Tax Identification Number (TIN) with Howard Fine, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Associated Retinal Consultants LLC	DE	Ophthalmology Physician	$0	$25.2M
Rohit Lakhanpal	MD	Retina Specialist (Ophthalmology) Physician	$6.1M	$0
Vinod Voleti	NJ	Retina Specialist (Ophthalmology) Physician	$4.1M	$0
Sumit Shah	NJ	Retina Specialist (Ophthalmology) Physician	$4.1M	$0
Newman Sund	MD	Ophthalmology Physician	$4M	$0
Eric Suan	MD	Ophthalmology Physician	$3.8M	$0
Matthew Speicher	MD	Ophthalmology Physician	$3.7M	$0
Timothy Polk	MD	Ophthalmology Physician	$3.5M	$0
Jonathan Prenner	NJ	Retina Specialist (Ophthalmology) Physician	$3.4M	$0
David Kim	NJ	Retina Specialist (Ophthalmology) Physician	$3.4M	$0

Nearby Providers

Other providers in the same ZIP code as Howard Fine, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Children's Specialized Hospital	NJ	Children's Rehabilitation Hospital	$0	$200M
Robert Wood Johnson University Hospital, Inc	NJ	General Acute Care Hospital	$0	$198.3M
Saint Peter's University Hospital	NJ	General Acute Care Hospital	$0	$185.5M
Diya Care Inc	NJ	Home Health Agency	$0	$139.8M
Golden Path Adult Day Health Care Inc.	NJ	Adult Day Care Clinic/Center	$0	$17.7M
New Brunswick Board Of Education	NJ	Local Education Agency (LEA)	$0	$12.7M
Care We Love, LLC	NJ	Home Health Agency	$0	$11.2M
Damon House Inc.	NJ	Substance Abuse Rehabilitation Facility	$0	$9.8M
Southern Bank Emergency Physicians LLC	NJ	Emergency Medicine Physician	$0	$9.2M
New Brunswick Counseling Center	NJ	Substance Use Disorder Rehabilitation Clinic/Center	$174.7K	$9M

Howard Fine — Billing Profile & Reimbursement Data

Sign up for Howard Fine — Billing Profile & Reimbursement Data policy alerts

Howard Fine — Billing Profile & Reimbursement Data

Sign up for Howard Fine — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References